par SARTORIUS STED BIO (EPA:DIM)
Sartorius Stedim Biotech SA: Half-year liquidity contract statement for Sartorius Stedim Biotech
Sartorius Stedim Biotech SA Aubagne, July 5, 2023
Half-year liquidity contract statement for Sartorius Stedim Biotech
Under the liquidity contract entered into between Sartorius Stedim Biotech and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2023:
As a reminder the following resources appeared on the last half year statement on 31 December 2022 on the liquidity account:
The following resources appeared on the liquidity account when the activity started:
The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd 2021 renewing the implementation of liquidity contracts for shares as an accepted market practice.
A profile of Sartorius Stedim Biotech Sartorius Stedim Biotech is a leading international partner of the biopharmaceutical industry. As a provider of innovative solutions, the company based in Aubagne, France, helps its customers to manufacture biotech medications safely, rapidly and economically. The shares of Sartorius Stedim Biotech S.A. are quoted on the Euronext Paris. The company has a strong global reach with manufacturing and R&D sites as well as sales entities in Europe, North America and Asia. Sartorius Stedim Biotech delivers significant organic growth and regularly expands its portfolio through acquisitions of complementary technologies. In fiscal 2022, the company generated sales revenue of around 3.5 billion euros. At the end of 2022, around 12,000 employees were working for customers around the globe.
Contact Petra Müller Head of Investor Relations +49 (0)551.308.6035 Petra.mueller2@sartorius.com
Sartorius Stedim Biotech S.A. Z.I. Les Paluds Avenue de Jouques, CS 91051 13781 Aubagne Cedex, France Phone: +33.(0)4.42.84.56.00 Fax: +33.(0)4.42.84.56.19 www.sartorius.com
|